Do analysts recommend CMMB or VIVS?

Chemomab Therapeutics currently has a consensus target price of $25.00, suggesting a potential upside of 1,386.33%. Given Chemomab Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Chemomab Therapeutics is more favorable than VivoSim Labs. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chemomab Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor CMMB or VIVS?

In the previous week, VivoSim Labs had 3 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 6 mentions for VivoSim Labs and 3 mentions for Chemomab Therapeutics. Chemomab Therapeutics' average media sentiment score of 0.53 beat VivoSim Labs' score of 0.41 indicating that Chemomab Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Chemomab Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive VivoSim Labs 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate VIVS or PHXM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings & valuation, VIVS or PHXM?

PHAXIAM Therapeutics has lower revenue, but higher earnings than VivoSim Labs. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio VivoSim Labs $140K 19.58 -$2.48M -$3.15 N/A PHAXIAM Therapeutics N/A N/A -$240K N/A N/A

Do analysts rate BCLI or VIVS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainstorm Cell Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor BCLI or VIVS?

In the previous week, VivoSim Labs had 5 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 6 mentions for VivoSim Labs and 1 mentions for Brainstorm Cell Therapeutics. Brainstorm Cell Therapeutics' average media sentiment score of 0.75 beat VivoSim Labs' score of 0.41 indicating that Brainstorm Cell Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Brainstorm Cell Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive VivoSim Labs 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer APRE or VIVS?

Aprea Therapeutics currently has a consensus target price of $4.07, indicating a potential upside of 412.17%. Given Aprea Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Aprea Therapeutics is more favorable than VivoSim Labs. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aprea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor APRE or VIVS?

In the previous week, VivoSim Labs had 3 more articles in the media than Aprea Therapeutics. MarketBeat recorded 6 mentions for VivoSim Labs and 3 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 1.29 beat VivoSim Labs' score of 0.41 indicating that Aprea Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aprea Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive VivoSim Labs 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer BON or VIVS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bon Natural Life 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, BON or VIVS?

Bon Natural Life has higher revenue and earnings than VivoSim Labs. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bon Natural Life $18.67M 0.51 -$2M N/A N/A VivoSim Labs $140K 19.58 -$2.48M -$3.15 N/A

VivoSim Labs (VIVS) Competitors

$1.05 -0.02 (-1.87%)

As of 12:51 PM Eastern

Compare

VIVS vs. CMMB, PHXM, BCLI, APRE, and BON

Should you buy VivoSim Labs stock or one of its competitors? MarketBeat compares VivoSim Labs with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with VivoSim Labs include Chemomab Therapeutics (CMMB), PHAXIAM Therapeutics (PHXM), Brainstorm Cell Therapeutics (BCLI), Aprea Therapeutics (APRE), and Bon Natural Life (BON). These companies are all part of the "pharmaceutical products" industry.

How does VivoSim Labs compare to Chemomab Therapeutics?

Chemomab Therapeutics (NASDAQ:CMMB) and VivoSim Labs (NASDAQ:VIVS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

46.1% of Chemomab Therapeutics shares are owned by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are owned by institutional investors. 11.9% of Chemomab Therapeutics shares are owned by insiders. Comparatively, 2.5% of VivoSim Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Chemomab Therapeutics currently has a consensus target price of $25.00, suggesting a potential upside of 1,386.33%. Given Chemomab Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Chemomab Therapeutics is more favorable than VivoSim Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

VivoSim Labs has higher revenue and earnings than Chemomab Therapeutics. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A
VivoSim Labs	$140K	19.58	-$2.48M	-$3.15	N/A

In the previous week, VivoSim Labs had 3 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 6 mentions for VivoSim Labs and 3 mentions for Chemomab Therapeutics. Chemomab Therapeutics' average media sentiment score of 0.53 beat VivoSim Labs' score of 0.41 indicating that Chemomab Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Chemomab Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
VivoSim Labs	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Chemomab Therapeutics has a net margin of 0.00% compared to VivoSim Labs' net margin of -861.27%. VivoSim Labs' return on equity of -15.51% beat Chemomab Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-89.03%	-79.68%
VivoSim Labs	-861.27%	-15.51%	-11.31%

Chemomab Therapeutics has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, VivoSim Labs has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market.

Summary

Chemomab Therapeutics beats VivoSim Labs on 8 of the 15 factors compared between the two stocks.

How does VivoSim Labs compare to PHAXIAM Therapeutics?

VivoSim Labs (NASDAQ:VIVS) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

VivoSim Labs has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, meaning that its share price is 135% more volatile than the broader market.

PHAXIAM Therapeutics has a net margin of 0.00% compared to VivoSim Labs' net margin of -861.27%. PHAXIAM Therapeutics' return on equity of 0.00% beat VivoSim Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VivoSim Labs	-861.27%	-15.51%	-11.31%
PHAXIAM Therapeutics	N/A	N/A	N/A

8.2% of VivoSim Labs shares are held by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 2.5% of VivoSim Labs shares are held by insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, VivoSim Labs had 6 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 6 mentions for VivoSim Labs and 0 mentions for PHAXIAM Therapeutics. VivoSim Labs' average media sentiment score of 0.41 beat PHAXIAM Therapeutics' score of 0.00 indicating that VivoSim Labs is being referred to more favorably in the media.

Company	Overall Sentiment
VivoSim Labs	Neutral
PHAXIAM Therapeutics	Neutral

PHAXIAM Therapeutics has lower revenue, but higher earnings than VivoSim Labs.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VivoSim Labs	$140K	19.58	-$2.48M	-$3.15	N/A
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A

Summary

VivoSim Labs beats PHAXIAM Therapeutics on 6 of the 11 factors compared between the two stocks.

How does VivoSim Labs compare to Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and VivoSim Labs (NASDAQ:VIVS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are held by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are held by company insiders. Comparatively, 2.5% of VivoSim Labs shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, VivoSim Labs had 5 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 6 mentions for VivoSim Labs and 1 mentions for Brainstorm Cell Therapeutics. Brainstorm Cell Therapeutics' average media sentiment score of 0.75 beat VivoSim Labs' score of 0.41 indicating that Brainstorm Cell Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Brainstorm Cell Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
VivoSim Labs	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

VivoSim Labs has higher revenue and earnings than Brainstorm Cell Therapeutics. Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.64	N/A
VivoSim Labs	$140K	19.58	-$2.48M	-$3.15	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainstorm Cell Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Brainstorm Cell Therapeutics has a net margin of 0.00% compared to VivoSim Labs' net margin of -861.27%. Brainstorm Cell Therapeutics' return on equity of 0.00% beat VivoSim Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%
VivoSim Labs	-861.27%	-15.51%	-11.31%

Brainstorm Cell Therapeutics has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market. Comparatively, VivoSim Labs has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market.

Summary

Brainstorm Cell Therapeutics beats VivoSim Labs on 8 of the 13 factors compared between the two stocks.

How does VivoSim Labs compare to Aprea Therapeutics?

Aprea Therapeutics (NASDAQ:APRE) and VivoSim Labs (NASDAQ:VIVS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

VivoSim Labs has a net margin of -861.27% compared to Aprea Therapeutics' net margin of -4,405.59%. VivoSim Labs' return on equity of -15.51% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aprea Therapeutics	-4,405.59%	-61.03%	-50.24%
VivoSim Labs	-861.27%	-15.51%	-11.31%

Aprea Therapeutics currently has a consensus target price of $4.07, indicating a potential upside of 412.17%. Given Aprea Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Aprea Therapeutics is more favorable than VivoSim Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, VivoSim Labs had 3 more articles in the media than Aprea Therapeutics. MarketBeat recorded 6 mentions for VivoSim Labs and 3 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 1.29 beat VivoSim Labs' score of 0.41 indicating that Aprea Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aprea Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
VivoSim Labs	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aprea Therapeutics has a beta of 1.51, suggesting that its stock price is 51% more volatile than the broader market. Comparatively, VivoSim Labs has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market.

34.2% of Aprea Therapeutics shares are owned by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are owned by institutional investors. 10.5% of Aprea Therapeutics shares are owned by insiders. Comparatively, 2.5% of VivoSim Labs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

VivoSim Labs has lower revenue, but higher earnings than Aprea Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aprea Therapeutics	$290K	33.90	-$12.60M	-$1.54	N/A
VivoSim Labs	$140K	19.58	-$2.48M	-$3.15	N/A

Summary

Aprea Therapeutics beats VivoSim Labs on 10 of the 16 factors compared between the two stocks.

How does VivoSim Labs compare to Bon Natural Life?

Bon Natural Life (NASDAQ:BON) and VivoSim Labs (NASDAQ:VIVS) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

Bon Natural Life has higher revenue and earnings than VivoSim Labs.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bon Natural Life	$18.67M	0.51	-$2M	N/A	N/A
VivoSim Labs	$140K	19.58	-$2.48M	-$3.15	N/A

In the previous week, VivoSim Labs had 5 more articles in the media than Bon Natural Life. MarketBeat recorded 6 mentions for VivoSim Labs and 1 mentions for Bon Natural Life. Bon Natural Life's average media sentiment score of 1.91 beat VivoSim Labs' score of 0.41 indicating that Bon Natural Life is being referred to more favorably in the media.

Company	Overall Sentiment
Bon Natural Life	Very Positive
VivoSim Labs	Neutral

Bon Natural Life has a beta of -0.17, meaning that its stock price is 117% less volatile than the broader market. Comparatively, VivoSim Labs has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bon Natural Life	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

0.6% of Bon Natural Life shares are held by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are held by institutional investors. 26.5% of Bon Natural Life shares are held by insiders. Comparatively, 2.5% of VivoSim Labs shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Bon Natural Life has a net margin of 0.00% compared to VivoSim Labs' net margin of -861.27%. Bon Natural Life's return on equity of 0.00% beat VivoSim Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bon Natural Life	N/A	N/A	N/A
VivoSim Labs	-861.27%	-15.51%	-11.31%

Summary

Bon Natural Life beats VivoSim Labs on 7 of the 11 factors compared between the two stocks.

Get VivoSim Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VIVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VIVS vs. The Competition

Export

Metric	VivoSim Labs	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.74M	$3.66B	$6.80B	$12.58B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	-0.33	21.54	27.48	25.45
Price / Sales	19.58	343.84	541.47	103.18
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	0.19	8.73	10.97	6.65
Net Income	-$2.48M	$23.87M	$3.57B	$336.83M
7 Day Performance	-3.67%	3.76%	2.80%	3.00%
1 Month Performance	-18.60%	3.79%	1.93%	0.56%
1 Year Performance	-27.59%	67.44%	36.49%	30.42%

VivoSim Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VIVS VivoSim Labs	1.0269 of 5 stars	$1.05 -1.9%	N/A	-27.2%	$2.74M	$140K	N/A	20	Short Interest Decrease
CMMB Chemomab Therapeutics	2.3893 of 5 stars	$1.56 +0.6%	$25.00 +1,502.6%	-65.1%	$11.16M	N/A	N/A	20	Short Interest Increase
PHXM PHAXIAM Therapeutics	N/A	$3.10 flat	N/A	N/A	$10.58M	N/A	N/A	49
BCLI Brainstorm Cell Therapeutics	0.5914 of 5 stars	$0.96 +2.1%	N/A	-10.7%	$10.56M	N/A	N/A	40
APRE Aprea Therapeutics	4.0154 of 5 stars	$0.79 -2.3%	$4.07 +414.8%	-52.5%	$10.01M	$290K	N/A	7	News Coverage Positive News Short Interest Decrease Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VIVS) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

VivoSim Labs (VIVS) Competitors

VIVS vs. CMMB, PHXM, BCLI, APRE, and BON

How does VivoSim Labs compare to Chemomab Therapeutics?

Summary

How does VivoSim Labs compare to PHAXIAM Therapeutics?

Summary

How does VivoSim Labs compare to Brainstorm Cell Therapeutics?

Summary

How does VivoSim Labs compare to Aprea Therapeutics?

Summary

How does VivoSim Labs compare to Bon Natural Life?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIVS vs. The Competition

VivoSim Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

VivoSim Labs (VIVS) Competitors

VIVS vs. CMMB, PHXM, BCLI, APRE, and BON

How does VivoSim Labs compare to Chemomab Therapeutics?

Do institutionals & insiders hold more shares of CMMB or VIVS?

Do analysts recommend CMMB or VIVS?

Which has higher valuation and earnings, CMMB or VIVS?

Does the media favor CMMB or VIVS?

Is CMMB or VIVS more profitable?

Which has more risk & volatility, CMMB or VIVS?

Summary

How does VivoSim Labs compare to PHAXIAM Therapeutics?

Do analysts rate VIVS or PHXM?

Which has more risk and volatility, VIVS or PHXM?

Is VIVS or PHXM more profitable?

Do insiders & institutionals believe in VIVS or PHXM?

Does the media refer more to VIVS or PHXM?

Which has higher earnings & valuation, VIVS or PHXM?

Summary

How does VivoSim Labs compare to Brainstorm Cell Therapeutics?

Do insiders and institutionals have more ownership in BCLI or VIVS?

Does the media favor BCLI or VIVS?

Which has higher valuation and earnings, BCLI or VIVS?

Do analysts rate BCLI or VIVS?

Is BCLI or VIVS more profitable?

Which has more risk & volatility, BCLI or VIVS?

Summary

How does VivoSim Labs compare to Aprea Therapeutics?

Is APRE or VIVS more profitable?

Do analysts prefer APRE or VIVS?

Does the media favor APRE or VIVS?

Which has more risk & volatility, APRE or VIVS?

Do insiders & institutionals believe in APRE or VIVS?

Which has higher earnings and valuation, APRE or VIVS?

Summary

How does VivoSim Labs compare to Bon Natural Life?

Which has stronger earnings and valuation, BON or VIVS?

Does the media favor BON or VIVS?

Which has more risk and volatility, BON or VIVS?

Do analysts prefer BON or VIVS?

Do insiders and institutionals hold more shares of BON or VIVS?

Is BON or VIVS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIVS vs. The Competition

VivoSim Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools